TECH – Bio-Techne Corp

Latest News & Stock Analysis

Bio-Techne Corporation (TECH) develops, manufactures, and sells biotechnology products and instruments worldwide. It operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment offers reagents such as cytokines and growth factors, antibodies, cell selection and activation products, and cell culture reagents. The Diagnostics and Genomics segment provides clinical controls, molecular diagnostics, and exosome diagnostics. Bio-Techne’s innovative approach to producing high-quality reagents and diagnostic tools makes it a key player in the life sciences and clinical diagnostics markets. Investors interested in biotech stocks often look to Bio-Techne for its consistent performance and growth potential. Stay updated with the latest news on TECH and in-depth stock analysis to make informed investment decisions.

Technion: Serial Acquirer Struggles to Deliver Promised Returns
TECH

Technion: Serial Acquirer Struggles to Deliver Promised Returns

by | 19/04/2025 09:00 AM | TECH

🤔 Technion, a Swedish serial acquirer focused on industrial and niche companies, is under scrutiny for failing to meet its promised 20% return on investment target, currently achieving only 6% over the last five years.

📉 Legacy businesses linked to real estate are performing poorly, negatively impacting organic growth and operating margins, raising concerns about the overall strategy execution.

🔄 High CFO turnover and reliance on future performance improvements create uncertainty, placing the stock in a 'standby' mode despite recent increased acquisition activity in the UK.

Read more!